Literature DB >> 11509618

Vpr is preferentially targeted by CTL during HIV-1 infection.

M Altfeld1, M M Addo, R L Eldridge, X G Yu, S Thomas, A Khatri, D Strick, M N Phillips, G B Cohen, S A Islam, S A Kalams, C Brander, P J Goulder, E S Rosenberg, B D Walker.   

Abstract

The HIV-1 accessory proteins Vpr, Vpu, and Vif are essential for viral replication, and their cytoplasmic production suggests that they should be processed for recognition by CTLs. However, the extent to which these proteins are targeted in natural infection, as well as precise CTL epitopes within them, remains to be defined. In this study, CTL responses against HIV-1 Vpr, Vpu, and Vif were analyzed in 60 HIV-1-infected individuals and 10 HIV-1-negative controls using overlapping peptides spanning the entire proteins. Peptide-specific IFN-gamma production was measured by ELISPOT assay and flow-based intracellular cytokine quantification. HLA class I restriction and cytotoxic activity were confirmed after isolation of peptide-specific CD8(+) T cell lines. CD8(+) T cell responses against Vpr, Vpu, and Vif were found in 45%, 2%, and 33% of HIV-1-infected individuals, respectively. Multiple CTL epitopes were identified in functionally important regions of HIV-1 Vpr and Vif. Moreover, in infected individuals in whom the breadth of HIV-1-specific responses was assessed comprehensively, Vpr and p17 were the most preferentially targeted proteins per unit length by CD8(+) T cells. These data indicate that despite the small size of these proteins Vif and Vpr are frequently targeted by CTL in natural HIV-1 infection and contribute importantly to the total HIV-1-specific CD8(+) T cell responses. These findings will be important in evaluating the specificity and breadth of immune responses during acute and chronic infection, and in the design and testing of candidate HIV vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509618     DOI: 10.4049/jimmunol.167.5.2743

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.

Authors:  Marcus Altfeld; Jan van Lunzen; Nicole Frahm; Xu G Yu; Claus Schneider; Robert L Eldridge; Margaret E Feeney; Dirk Meyer-Olson; Hans-Juergen Stellbrink; Bruce D Walker
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  The dose-dependent H2O2 stress response promotes increased survival for Schizosaccharomyces pombe cells expressing HIV-1 Vpr.

Authors:  J Antal; M Pesti
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

3.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

4.  Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation.

Authors:  Karina Yusim; Can Kesmir; Brian Gaschen; Marylyn M Addo; Marcus Altfeld; Søren Brunak; Alexandre Chigaev; Vincent Detours; Bette T Korber
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

5.  Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection.

Authors:  Xu G Yu; Marylyn M Addo; Eric S Rosenberg; William R Rodriguez; Paul K Lee; Cecily A Fitzpatrick; Mary N Johnston; Daryld Strick; Philip J R Goulder; Bruce D Walker; Marcus Altfeld
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.

Authors:  Jean-Pierre Routy; Mohamed-Rachid Boulassel; Bader Yassine-Diab; Charles Nicolette; Don Healey; Renu Jain; Claire Landry; Oleg Yegorov; Irina Tcherepanova; Tamara Monesmith; Lothar Finke; Rafick-Pierre Sékaly
Journal:  Clin Immunol       Date:  2009-11-04       Impact factor: 3.969

7.  Optimizing peptide matrices for identifying T-cell antigens.

Authors:  Melissa L Precopio; Tiffany R Butterfield; Joseph P Casazza; Susan J Little; Douglas D Richman; Richard A Koup; Mario Roederer
Journal:  Cytometry A       Date:  2008-11       Impact factor: 4.355

8.  Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection.

Authors:  Todd M Allen; Marcus Altfeld; Xu G Yu; Kristin M O'Sullivan; Mathias Lichterfeld; Sylvie Le Gall; Mina John; Bianca R Mothe; Paul K Lee; Elizabeth T Kalife; Daniel E Cohen; Kenneth A Freedberg; Daryld A Strick; Mary N Johnston; Alessandro Sette; Eric S Rosenberg; Simon A Mallal; Philip J R Goulder; Christian Brander; Bruce D Walker
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 9.  HIV-1 viral protein R (Vpr) and its interactions with host cell.

Authors:  Ge Li; Michael Bukrinsky; Richard Y Zhao
Journal:  Curr HIV Res       Date:  2009-03       Impact factor: 1.581

10.  The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.

Authors:  Irina Tcherepanova; Aijing Starr; Brad Lackford; Melissa D Adams; Jean-Pierre Routy; Mohamed Rachid Boulassel; David Calderhead; Don Healey; Charles Nicolette
Journal:  PLoS One       Date:  2009-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.